Company news

ProQR Therapeutics N.V. news in 2019

ProQR Therapeutics N.V.'s news releases, calls and decks from 2019, newest first.

View company

ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa

December 10, 2019

ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa

November 20, 2019

ProQR Announces Recent Progress and Financial Results for the Third Quarter of 2019

November 5, 2019

ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10

October 14, 2019

ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares

October 14, 2019

ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients

October 9, 2019

ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa

September 8, 2019

ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10

April 14, 2019

Decks in 2019